This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Experts
Rebecca Fink
Principal Research Scientist
Contact
RebeccaFink@westat.comOverview
Rebecca Fink, MPH, is a Principal Research Scientist with 13 years of experience designing and implementing multisite epidemiologic research studies, online panel surveys, public health interventions, and evaluations for clients such as CDC, NIH, and HRSA. Her areas of expertise include infectious diseases epidemiology, maternal and child health, multisite study coordination, protocol development, survey design, data management, and data analysis. Fink has coauthored numerous peer-reviewed publications.
Education
- MPH, School of Public Health, Boston University, Epidemiology and Biostatistics
- BS (magna cum laude), Boston University, Health Science
-
Use of US blood donors for national serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 antibodies: Basis for an expanded national donor serosurveillance program
74,
Clinical Infectious Diseases
January 2022
M. Stone, C. Di Germanio, D.J. Wright, H. Sulaeman, H. Dave, Rebecca Fink, E.P. Notari, et al.
DOILink for: Use of US blood donors for national serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 antibodies: Basis for an expanded national donor serosurveillance program -
How do we...form and coordinate a national serosurvey of SARS-CoV-2 within the blood collection industry?
62,
Transfusion
January 2022
Rebecca Fink, L. Fisher, H. Sulaeman, H. Dave, M.E. Levy, L. McCann, C. Di Germanio, et al.
DOILink for: How do we...form and coordinate a national serosurvey of SARS-CoV-2 within the blood collection industry? -
Population-weighted seroprevalence from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, vaccination, and hybrid immunity among US blood donations from January to December 2021
75,
Clinical Infectious Diseases
January 2022
M.P. Busch, S.L. Stramer, M. Stone, E.A. Yu, E. Grebe, E. Notari, P. Saa, et al.
DOILink for: Population-weighted seroprevalence from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, vaccination, and hybrid immunity among US blood donations from January to December 2021